alternative to glp-1 that insurance covers At the beginning of this year, Medi-Cal cut all coverage for medication for obesity treatment. Very disappointing news. But we must remember we have other effective treatment options that we Perspectives from employers on the
Description
An important drug discovery challenge

It is essential to view these dietary and lifestyle changes not as a temporary "diet" undertaken solely while on medication, but as the foundation for long-term health and well-being

The dose-dependent effect of GLP-1 on decelerating gastric emptying plays a substantial role in improving postprandial glycemic concentrations to the extent that postprandial insulin secretion may no longer be stimulated or could even be reduced (154, 155) ( Figure 1 Section D)

2021;182 doi: 10.1016/j.nlm.2021.107463

& Levien, T
The proposed clinical trial endpoints are the resolution of steatohepatitis without worsening or liver fibrosis and/or improvement in liver fibrosis one stage or greater without worsening of steatohepatitis
